CXCR4抗体;CXCR4 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12488(CXCR4 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P12488(CXCR4 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

CXCR4 antibodies target the C-X-C chemokine receptor type 4 (CXCR4), a G protein-coupled receptor (GPCR) that binds stromal cell-derived factor-1 (SDF-1/CXCL12). CXCR4 plays critical roles in immune cell trafficking, stem cell homing, embryonic development, and cancer metastasis. Its dysregulation is linked to various diseases, including HIV infection, cancer progression, and autoimmune disorders. In HIV, CXCR4 acts as a co-receptor for viral entry into T-cells, making it a therapeutic target. CXCR4 antibodies are designed to block receptor activity, potentially inhibiting HIV entry or disrupting cancer cell migration and metastasis.

In oncology, CXCR4 overexpression in tumors promotes metastasis by enhancing cell adhesion to distant tissues rich in CXCL12. Antibodies like ulocuplumab (BMS-936564) have been developed to block CXCR4-CXCL12 signaling, showing promise in preclinical and clinical studies for hematologic malignancies and solid tumors. These antibodies may also enhance chemotherapy efficacy by mobilizing cancer cells from protective niches. However, challenges include managing potential immune-related toxicities and overcoming compensatory signaling pathways.

Beyond therapeutics, CXCR4 antibodies are vital research tools for studying receptor expression, trafficking, and signaling mechanisms. They aid in identifying CXCR4-positive cell populations in flow cytometry or immunohistochemistry. Current research focuses on optimizing antibody specificity, developing bispecific antibodies, and combining CXCR4 inhibition with immunotherapy or targeted therapies to improve clinical outcomes.